798 results on '"Kimby, Eva"'
Search Results
152. The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
153. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
154. ADVANCES IN BIOLOGY AND THERAPY OF WALDENSTRÖM’S MACROGLOBULINEMIA: UPDATE ON TREATMENT RECOMMENDATIONS FROM THE THIRD INTERNATIONAL WORKSHOP ON WALDENSTRÖM’S MACROGLOBULINEMIA
155. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
156. Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features
157. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
158. microRNA-34b/con chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia
159. A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
160. T-Cell Frequencies In MCL Are Of Prognostic Importance In a Large Population-Based Cohort
161. Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey
162. Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
163. Safety and Immunogenicity Of Inactivated Varicella-Zoster Virus Vaccine In Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies
164. The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure
165. Ovarian cancer
166. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
167. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
168. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
169. Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
170. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression
171. Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis
172. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update.
173. Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden.
174. SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment
175. Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
176. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
177. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
178. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
179. Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial
180. Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998–2010
181. SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,
182. Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab
183. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
184. Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study
185. 4.28 FISH on Paraffin-Embedded Tissue Samples is Feasible and of Prognostic Importance in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
186. Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients
187. Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia
188. Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study
189. T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
190. High‐resolution genomic screening in mantle cell lymphoma—specific changes correlate with genomic complexity, the proliferation signature and survival
191. Gene Expression Profiling and Chromatin Immunoprecipitation Identify DBN1, SETMAR and HIG2 as Direct Targets of SOX11 in Mantle Cell Lymphoma
192. Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant
193. Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
194. Cytogenetic Abnormalities In the Spleen In CLL Patients.
195. Reply to U. Dührsen et al
196. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden
197. Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
198. BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study
199. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
200. A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.